Frensius-Kabi has announced that the FDA has approved the tocilizumab biosimilar, Tyenne (tocilizumab-aazg); the first TCZ biosimilar with both IV and subcutaneous formulations https://t.co/F3d8DKxpkU https://t.co/NSEqAcoBBo
Links:
Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and…
https://bit.ly/3Tqxc5E
Mar-10-2024
